Spring Bank Pharmaceuticals, Inc. (SBPH) EPS Estimated At $-0.57

October 2, 2018 - By Ash

Analysts expect Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) to report $-0.57 EPS on October, 30.They anticipate $0.18 EPS change or 46.15 % from last quarter’s $-0.39 EPS. After having $-0.29 EPS previously, Spring Bank Pharmaceuticals, Inc.’s analysts see 96.55 % EPS growth. The stock decreased 0.84% or $0.1 during the last trading session, reaching $11.78. About 3,462 shares traded. Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) has declined 11.31% since October 2, 2017 and is downtrending. It has underperformed by 26.93% the S&P500.

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid chemistry platform. The company has market cap of $190.66 million. The Company’s SMNH compounds are small divisions of nucleic acids that the firm creates to target and modulate the activity of specific proteins implicated in various disease states. It currently has negative earnings. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus.

More news for Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) were recently published by: Nasdaq.com, which released: “Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference” on September 17, 2018. Investorplace.com‘s article titled: “7 Lucrative Biotech Stocks With Up to 300% Upside” and published on September 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: